Trigemina reports positive results from TI-001 Phase IIa clinical trial for Chronic Daily Headache

Trigemina, Inc. (TI), a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache (CDH). The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.

CDH represents up to 3% of the US population, for which there currently is no effective treatment. Trigemina utilizes the recently elucidated nasal-cerebral pathway to directly target pain transmission in cranial nerves and the central nervous system, enabling important and effective new strategies for the treatment of acute and chronic pain.

In the trial, 40 CDH patients refractory to available medication underwent treatment with intranasal TI-001 versus placebo in a double blind, parallel trial. The treatment group demonstrated benefit in a wide range of metrics used to measure pain and secondary symptoms. Based on numeric pain scales, 50% of TI-001 treated patients reported at least a 50% reduction in pain at 4 hours compared to 11% of placebo treated patients - a statistically significant difference. In addition, 27% of TI-001 treated patients reported zero pain at 4 hours, compared to none of the placebo treated patients. Secondary symptoms including nausea, photophobia, and phonophobia also improved in the TI-001 group compared to the placebo group.

Trigemina CEO Daniel Jacobs, MD stated, "There is a significant effect size with the TI-001 treatment. With dose and formulation optimization still in progress, we were just looking for the first signs of a human response in this trial to validate our strong preclinical data. We were pleased to see that not only is there a clinical signal, but that it is robust. As we define the ideal dosing and formulation parameters, we look forward to even greater patient benefit. We continue to demonstrate that intranasal TI-001, an oxytocin formulation, has the potential to significantly reduce pain in CDH patients and improve the lives of millions of people suffering from this debilitating condition."

Source:

 Trigemina, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease